OR WAIT 15 SECS
Moderna and Chiesi Group are collaborating on the discovery and development of mRNA therapeutics to treat pulmonary arterial hypertension.
Biotechnology company, Moderna, and international research-focused healthcare group, Chiesi Farmaceutici (Chiesi Group), have announced a collaboration aimed at the discovery and development of messenger RNA (mRNA) therapeutics to treat pulmonary arterial hypertension (PAH).
The collaboration, which was announced in a Sept. 16, 2020 press release, will see Moderna leverage its mRNA technology and delivery platforms, alongside Chiesi’s expertise, to lead discovery efforts in PAH biology. Chiesi Group will lead the development and commercialization activities and will have the responsibility of funding the collaborative expenses.
“We are excited to begin this collaboration with Chiesi Group, which provides the opportunity to further leverage our mRNA and delivery technology,” said Stephen Hoge, president of Moderna, in the press release. “This new relationship continues our commitment to partner with companies that have unique expertise in serious diseases, and who share our vision of using mRNA therapeutics to address the unmet needs of patients.”
“Chiesi Group is at the forefront of innovation and discovery of novel therapies for people affected by diseases with high unmet medical need,” added Ugo Di Francesco, CEO of Chiesi Group, in the press release. “And the agreement with Moderna, a leader in mRNA science and delivery, confirms our commitment to better serve patients and healthcare professionals with transformative solutions.”
Under the terms of the collaboration, Moderna will receive a $25 million payment upfront and is eligible for more than $400 million in development, regulatory, and commercial milestones, in addition to tiered double-digit royalties on net sales.